Σύγκριση μεθόδων
Εξετάστε τις επιλεγμένες μεθόδους δίπλα-δίπλα· οι γραμμές που διαφέρουν επισημαίνονται.
| ΕΟΚΕ ΠΟΙΟΤΗΤΑ ΖΩΗΣ-C30× | Ερωτηματολόγιο Νόσου Parkinson-39× | |
|---|---|---|
| Πεδίο | Εκβάσεις Υγείας | Εκβάσεις Υγείας |
| Οικογένεια | Process / pipeline | Process / pipeline |
| Έτος προέλευσης≠ | 1993 | 1997 |
| Δημιουργός≠ | Nico Aaronson et al. | Crispin Jenkinson et al. |
| Τύπος | Self-report quality of life questionnaire | Self-report quality of life questionnaire |
| Θεμελιώδης πηγή≠ | Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376. DOI ↗ | Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age and Ageing, 26(5), 353-357. DOI ↗ |
| Εναλλακτικές ονομασίες | QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale | PDQ-39, Parkinson's Disease Questionnaire, PDQ |
| Συναφείς≠ | 5 | 4 |
| Σύνοψη≠ | The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care. | The PDQ-39 is the most widely used patient-reported outcome measure for Parkinson's disease quality of life. Developed by Crispin Jenkinson and colleagues in 1997, this 39-item self-report questionnaire comprehensively assesses how Parkinson's symptoms affect daily functioning, emotional well-being, stigma, social support, and cognitive-communication abilities. It is the recommended instrument in major Parkinson's disease clinical trials and forms a core component of outcome measurement in movement disorders. |
| ScholarGateΣύνολο δεδομένων ↗ |
|
|